Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.

Abstract

From October 1985 to December 1986, 25 patients with advanced prostatic carcinoma were entered in a phase II trial and were administered fluorouracil (F) 600 mg/m2, on days 1 and 2, doxorubicin (A) 40 mg/m2, on day 1, and cisplatin (P) 90 mg/m2, on day 1, every month. The response was evaluated after three cycles of chemotherapy according to National Prostatic Cancer Project criteria. There were no complete remission, 1 partial remission, 13 stabilizations, 11 progressions. Toxicity was assessed using WHO criteria. Alopecia and vomiting were universal; there were 11 grade 1 anemias, 2 aplasias, and 1 grade 1 renal toxicity. A FAP regimen appears to exert a marginal effect in advanced prostatic carcinoma.

• Authors: H Lupera, J P Droz, G Piot, P Lapleige, P Fargeot, C Theodore
• Journal: Oncology (Oncology) Vol. 46 Issue 6 Pg. 372-4 ( 1989) ISSN: 0030-2414 [Print] Switzerland
• PMID: 2587004 (Publication Type: Journal Article)

Chemical References

• Doxorubicin
• Cisplatin
• Fluorouracil

Topics

• Adenocarcinoma (drug therapy, pathology)
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cisplatin (administration & dosage, adverse effects)
• Doxorubicin (administration & dosage, adverse effects)
• Drug Evaluation
• Fluorouracil (administration & dosage, adverse effects)
• Humans
• Male
• Middle Aged
• Neoplasm Metastasis
• Prostatic Neoplasms (drug therapy, pathology)